MAPT and Alzheimer disease: Overall, our results suggest p-tau217 is an appropriate biomarker for monitoring the presence of amyloid and tau, as it is particularly low in subjects without AD pathology and increases rapidly over the significance threshold with the occurrence of amyloidosis and tau pathology.